Advertisement

Topics

Rebiotix starts enrolment in Phase III trial of RBX2660 for C. diff infection

19:00 EDT 8 Aug 2017 | Net Resources International

US-based clinical-stage microbiome firm Rebiotix has started patient enrolment in a Phase III clinical trial of RBX2660 to prevent recurrent Clostridium difficile (C. diff) infection.

Original Article: Rebiotix starts enrolment in Phase III trial of RBX2660 for C. diff infection

NEXT ARTICLE

More From BioPortfolio on "Rebiotix starts enrolment in Phase III trial of RBX2660 for C. diff infection"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...